Lyell Immunopharma, Inc. (LYEL)

Lyell Immunopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-331.4	-342.99	-234.63	-183.12	-250.22	-204.47
Depreciation & Amortization	16.28	19.63	20.25	18.02	13.62	4.29
Loss (Gain) From Sale of Assets	5.09	1.34	1.51	0.1	1.21	-4.88
Asset Writedown & Restructuring Costs	139.92	138.48	-	-	-	-
Loss (Gain) From Sale of Investments	-9.3	-1.71	3.33	1.15	38.35	0.54
Stock-Based Compensation	26.73	33.14	47.08	81.92	62.2	33.26
Other Operating Activities	-9.45	-7.17	-4.65	-5.62	4.57	10.72
Change in Accounts Payable	-4.49	-3.23	1.46	0.67	0.09	-0.28
Change in Unearned Revenue	-	-	-	-84.65	-10.51	-7.76
Change in Other Net Operating Assets	-4.87	0.11	1.96	1.97	14.43	7.7
Operating Cash Flow	-171.48	-162.39	-163.69	-169.56	-126.25	-160.87
Capital Expenditures	-0.52	-0.46	-2.69	-24.28	-65.5	-51.48
Cash Acquisitions	-31.35	-31.35	-	-	-	-
Investment in Securities	169.4	154.23	186.73	12.74	-56.07	-222.04
Investing Cash Flow	137.54	122.42	184.05	-11.54	-121.57	-273.52
Issuance of Common Stock	0.62	1.4	2.2	11.1	401.24	0.37
Repurchase of Common Stock	-	-0.08	-0.46	-0.46	-	-11.81
Financing Cash Flow	0.62	1.33	1.74	10.64	401.24	476.79
Net Cash Flow	-33.32	-38.64	22.1	-170.46	153.42	42.4
Free Cash Flow	-172	-162.86	-166.38	-193.83	-191.75	-212.36
Free Cash Flow Margin	-286661.67%	-266980.33%	-127984.62%	-228.89%	-1800.50%	-2737.94%
Free Cash Flow Per Share	-12.21	-12.46	-13.26	-15.69	-28.22	-320.34
Levered Free Cash Flow	-81.78	-67.56	-90.36	-53.9	-129.82	-128
Unlevered Free Cash Flow	-81.78	-67.56	-90.36	-53.9	-129.82	-128
Change in Working Capital	-9.36	-3.12	3.42	-82.02	4.01	-0.34

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q